- Home
- ISPC vs GRI Comparison
ISPC vs GRI Comparison
Compare ISPC & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISPC
- GRI
- Stock Information
- Founded
- ISPC 2009
- GRI 2018
- Country
- ISPC United States
- GRI United States
- Employees
- ISPC N/A
- GRI N/A
- Industry
- ISPC Precision Instruments
- GRI Biotechnology: Pharmaceutical Preparations
- Sector
- ISPC Health Care
- GRI Health Care
- Exchange
- ISPC Nasdaq
- GRI Nasdaq
- Market Cap
- ISPC 3.1M
- GRI 3.4M
- IPO Year
- ISPC 2021
- GRI N/A
- Fundamental
- Price
- ISPC $1.06
- GRI $1.82
- Analyst Decision
- ISPC
- GRI Strong Buy
- Analyst Count
- ISPC 0
- GRI 2
- Target Price
- ISPC N/A
- GRI $22.00
- AVG Volume (30 Days)
- ISPC 102.3K
- GRI 166.0K
- Earning Date
- ISPC 08-05-2025
- GRI 08-13-2025
- Dividend Yield
- ISPC N/A
- GRI N/A
- EPS Growth
- ISPC N/A
- GRI N/A
- EPS
- ISPC N/A
- GRI N/A
- Revenue
- ISPC $8,058,631.00
- GRI N/A
- Revenue This Year
- ISPC $35.93
- GRI N/A
- Revenue Next Year
- ISPC N/A
- GRI N/A
- P/E Ratio
- ISPC N/A
- GRI N/A
- Revenue Growth
- ISPC N/A
- GRI N/A
- 52 Week Low
- ISPC $0.86
- GRI $1.10
- 52 Week High
- ISPC $8.30
- GRI $43.69
- Technical
- Relative Strength Index (RSI)
- ISPC 51.12
- GRI 59.04
- Support Level
- ISPC $1.01
- GRI $1.53
- Resistance Level
- ISPC $1.15
- GRI $1.75
- Average True Range (ATR)
- ISPC 0.12
- GRI 0.17
- MACD
- ISPC 0.01
- GRI 0.06
- Stochastic Oscillator
- ISPC 47.06
- GRI 67.47
About ISPC iSpecimen Inc.
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.